Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of Oral Bivalent Norovirus Vaccine
NCT05626803Phase 2Completed
- Sponsor
- Vaxart, Inc.
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Viral Vector Vaccines, Drug Delivery Systems, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of VXA-GI.1.NN, VXA-G2.4-NS in norovirus infection, sponsored by Vaxart, Inc.. Started Jan 2023; status: completed.
02
Drugs
VXA-GI.1.NNVXA-G2.4-NS
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT05626803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626803.